Impact of HIV Infection on COVID-19 Outcomes Among Hospitalized Adults in the U.S
Background: Whether HIV infection is associated with differences in clinical outcomes among people hospitalized with COVID-19 is uncertain.
Objective: To evaluate the impact of HIV infection on COVID-19 outcomes among hospitalized patients.
Methods: Using the American Heart Association's COVID-19 Cardiovascular Disease registry, we used hierarchical mixed effects models to assess the association of HIV with in-hospital mortality accounting for patient demographics and comorbidities and clustering by hospital. Secondary outcomes included major adverse cardiac events (MACE), severity of illness, and length of stay (LOS).
Results: The registry included 21,528 hospitalization records of people with confirmed COVID-19 from 107 hospitals in 2020, including 220 people living with HIV (PLWH). PLWH were younger (56.0+/-13.0 versus 61.3+/-17.9 years old) and more likely to be male (72.3% vs 52.7%), Non-Hispanic Black (51.4% vs 25.4%), on Medicaid (44.5% vs 24.5), and active tobacco users (12.7% versus 6.5%).Of the study population, 36 PLWH (16.4%) had in-hospital mortality compared with 3,290 (15.4%) without HIV (Risk ratio 1.06, 95%CI 0.79-1.43; risk difference 0.9%, 95%CI -4.2 to 6.1%; p=0.71). After adjustment for age, sex, race, and insurance, HIV was not associated with in-hospital mortality (aOR 1.13; 95%CI 0.77-1.6; p 0.54) even after adding body mass index and comorbidities (aOR 1.15; 95%CI 0.78-1.70; p=0.48). HIV was not associated with MACE (aOR 0.99, 95%CI 0.69-1.44, p=0.91), severity of illness (aOR 0.96, 95%CI 0.62-1.50, p=0.86), or LOS (aOR 1.03; 95% CI 0.76-1.66, p=0.21).
Conclusion: HIV was not associated with adverse outcomes of COVID-19 including in-hospital mortality, MACE, or severity of illness.
Errataetall: |
UpdateIn: This article has been published with doi: 10.1097/qad.0000000000003129 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
---|---|
Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 07. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Durstenfeld, Matthew S [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Revised 01.04.2024 published: Electronic UpdateIn: This article has been published with doi: 10.1097/qad.0000000000003129 Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1101/2021.04.05.21254938 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM32406022X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM32406022X | ||
003 | DE-627 | ||
005 | 20240401231951.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.04.05.21254938 |2 doi | |
028 | 5 | 2 | |a pubmed24n1359.xml |
035 | |a (DE-627)NLM32406022X | ||
035 | |a (NLM)33851188 | ||
035 | |a (PII)2021.04.05.21254938 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Durstenfeld, Matthew S |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of HIV Infection on COVID-19 Outcomes Among Hospitalized Adults in the U.S |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 01.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a UpdateIn: This article has been published with doi: 10.1097/qad.0000000000003129 | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Background: Whether HIV infection is associated with differences in clinical outcomes among people hospitalized with COVID-19 is uncertain | ||
520 | |a Objective: To evaluate the impact of HIV infection on COVID-19 outcomes among hospitalized patients | ||
520 | |a Methods: Using the American Heart Association's COVID-19 Cardiovascular Disease registry, we used hierarchical mixed effects models to assess the association of HIV with in-hospital mortality accounting for patient demographics and comorbidities and clustering by hospital. Secondary outcomes included major adverse cardiac events (MACE), severity of illness, and length of stay (LOS) | ||
520 | |a Results: The registry included 21,528 hospitalization records of people with confirmed COVID-19 from 107 hospitals in 2020, including 220 people living with HIV (PLWH). PLWH were younger (56.0+/-13.0 versus 61.3+/-17.9 years old) and more likely to be male (72.3% vs 52.7%), Non-Hispanic Black (51.4% vs 25.4%), on Medicaid (44.5% vs 24.5), and active tobacco users (12.7% versus 6.5%).Of the study population, 36 PLWH (16.4%) had in-hospital mortality compared with 3,290 (15.4%) without HIV (Risk ratio 1.06, 95%CI 0.79-1.43; risk difference 0.9%, 95%CI -4.2 to 6.1%; p=0.71). After adjustment for age, sex, race, and insurance, HIV was not associated with in-hospital mortality (aOR 1.13; 95%CI 0.77-1.6; p 0.54) even after adding body mass index and comorbidities (aOR 1.15; 95%CI 0.78-1.70; p=0.48). HIV was not associated with MACE (aOR 0.99, 95%CI 0.69-1.44, p=0.91), severity of illness (aOR 0.96, 95%CI 0.62-1.50, p=0.86), or LOS (aOR 1.03; 95% CI 0.76-1.66, p=0.21) | ||
520 | |a Conclusion: HIV was not associated with adverse outcomes of COVID-19 including in-hospital mortality, MACE, or severity of illness | ||
650 | 4 | |a Preprint | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a HIV | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a human immunodeficiency virus | |
650 | 4 | |a outcomes | |
700 | 1 | |a Sun, Kaiwen |e verfasserin |4 aut | |
700 | 1 | |a Ma, Yifei |e verfasserin |4 aut | |
700 | 1 | |a Rodriguez, Fatima |e verfasserin |4 aut | |
700 | 1 | |a Secemsky, Eric A |e verfasserin |4 aut | |
700 | 1 | |a Parikh, Rushi V |e verfasserin |4 aut | |
700 | 1 | |a Hsue, Priscilla Y |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 07. Apr. |w (DE-627)NLM310900166 |7 nnns |
773 | 1 | 8 | |g year:2021 |g day:07 |g month:04 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.04.05.21254938 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2021 |b 07 |c 04 |